Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 1063 | 4.1169 |
09:34 ET | 1336 | 4.25 |
09:41 ET | 340 | 4.2 |
10:01 ET | 975 | 4.26 |
11:27 ET | 2163 | 4.2 |
11:31 ET | 665 | 4.12 |
11:51 ET | 4926 | 4.16 |
11:54 ET | 200 | 4.07 |
12:12 ET | 119 | 4.03 |
01:12 ET | 100 | 4.08 |
01:14 ET | 6803 | 4.092 |
01:17 ET | 200 | 4.12 |
01:19 ET | 1000 | 4.09 |
02:22 ET | 100 | 4.09 |
02:33 ET | 248 | 4.09 |
02:42 ET | 100 | 4.085 |
02:44 ET | 1059 | 4.1 |
03:27 ET | 100 | 4.07 |
03:39 ET | 503 | 4.04 |
03:41 ET | 254 | 4.04 |
03:48 ET | 100 | 4.09 |
03:57 ET | 874 | 4.09 |
03:59 ET | 1876 | 4.09 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 226.3M | -2.2x | --- |
Acumen Pharmaceuticals Inc | 230.7M | -3.6x | --- |
INmune Bio Inc | 222.2M | -5.5x | --- |
Compass Therapeutics Inc. | 220.1M | -4.6x | --- |
Ovid Therapeutics Inc | 222.3M | -4.3x | --- |
Boundless Bio Inc | 236.2M | 0.0x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $226.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.57 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.